Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma

Vinorelbine (Navelbine, VRL) is commonly used for platinum-resistant ovarian cancer and has been shown to be effective in patients with recurrent primary peritoneal carcinoma. Of VRL's major side effects, skin rash is uncommon, and, if it does occur, it is usually localized to site of injection...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammad, Mustafa M., Syrigos, Kostas N., Saif, M. Wasif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773891/
https://www.ncbi.nlm.nih.gov/pubmed/24073344
http://dx.doi.org/10.1155/2013/825717
_version_ 1782284443177713664
author Mohammad, Mustafa M.
Syrigos, Kostas N.
Saif, M. Wasif
author_facet Mohammad, Mustafa M.
Syrigos, Kostas N.
Saif, M. Wasif
author_sort Mohammad, Mustafa M.
collection PubMed
description Vinorelbine (Navelbine, VRL) is commonly used for platinum-resistant ovarian cancer and has been shown to be effective in patients with recurrent primary peritoneal carcinoma. Of VRL's major side effects, skin rash is uncommon, and, if it does occur, it is usually localized to site of injection. In this case report, a 71-year-old Hispanic female with primary peritoneal carcinoma received single agent VRL as fourth-line regimen, which she tolerated very well except for a skin rash related to VRL. The rash continued to progress throughout 6 cycles of VRL, and follow-up CT/PET scan demonstrated complete metabolic and radiological responses. We, therefore, believe that this rash was linked to VRL administration and correlated with response to therapy. Rash has been recognized as a useful surrogate marker with targeted agents such as cetuximab and erlotinib; to the best of our knowledge, this case report describes the first patient with a possible drug rash and its association with a positive outcome. This case report incites interest in further investigation of similar cases to support this observation, since there is a lack of reports of skin rash with VRL therapy.
format Online
Article
Text
id pubmed-3773891
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37738912013-09-26 Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma Mohammad, Mustafa M. Syrigos, Kostas N. Saif, M. Wasif Case Rep Dermatol Med Case Report Vinorelbine (Navelbine, VRL) is commonly used for platinum-resistant ovarian cancer and has been shown to be effective in patients with recurrent primary peritoneal carcinoma. Of VRL's major side effects, skin rash is uncommon, and, if it does occur, it is usually localized to site of injection. In this case report, a 71-year-old Hispanic female with primary peritoneal carcinoma received single agent VRL as fourth-line regimen, which she tolerated very well except for a skin rash related to VRL. The rash continued to progress throughout 6 cycles of VRL, and follow-up CT/PET scan demonstrated complete metabolic and radiological responses. We, therefore, believe that this rash was linked to VRL administration and correlated with response to therapy. Rash has been recognized as a useful surrogate marker with targeted agents such as cetuximab and erlotinib; to the best of our knowledge, this case report describes the first patient with a possible drug rash and its association with a positive outcome. This case report incites interest in further investigation of similar cases to support this observation, since there is a lack of reports of skin rash with VRL therapy. Hindawi Publishing Corporation 2013 2013-09-01 /pmc/articles/PMC3773891/ /pubmed/24073344 http://dx.doi.org/10.1155/2013/825717 Text en Copyright © 2013 Mustafa M. Mohammad et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mohammad, Mustafa M.
Syrigos, Kostas N.
Saif, M. Wasif
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma
title Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma
title_full Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma
title_fullStr Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma
title_full_unstemmed Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma
title_short Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma
title_sort association between rash and a positive drug response associated with vinorelbine in a patient with primary peritoneal carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773891/
https://www.ncbi.nlm.nih.gov/pubmed/24073344
http://dx.doi.org/10.1155/2013/825717
work_keys_str_mv AT mohammadmustafam associationbetweenrashandapositivedrugresponseassociatedwithvinorelbineinapatientwithprimaryperitonealcarcinoma
AT syrigoskostasn associationbetweenrashandapositivedrugresponseassociatedwithvinorelbineinapatientwithprimaryperitonealcarcinoma
AT saifmwasif associationbetweenrashandapositivedrugresponseassociatedwithvinorelbineinapatientwithprimaryperitonealcarcinoma